A 32-year-old man presents 2 years after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis. He reports increased stool frequency (12/day from baseline 5), urgency, cramping, low-grade fever, and minor rectal bleeding. Pouchoscopy shows diffuse erythema, granularity, friability, and superficial ulcerations confined to the pouch; biopsies confirm acute and chronic inflammation with a Pouchitis Disease Activity Index (PDAI) of 9. This is his first episode of pouchitis. Which of the following management approaches, marked **B** in the algorithm, is most appropriate for this acute presentation?
A. Observation without treatment, as acute pouchitis is self-limiting and resolves spontaneously within 2–4 weeks in most patients
B. Long-term high-dose systemic corticosteroids (prednisolone 40–60 mg daily) as first-line therapy to suppress the underlying IBD-like immune phenotype
C. Conversion to permanent end-ileostomy at the first episode to prevent recurrent inflammation and dysplasia
D. Empirical metronidazole 400 mg three times daily or ciprofloxacin 500 mg twice daily for 14 days, with escalation to maintenance or advanced therapy if recurrent or refractory disease develops
Explanation
Why empirical metronidazole or ciprofloxacin for 14 days is correct
The AGA, ESGE, and ECCO guidelines (2024 and prior consensus) recommend empirical antibiotic therapy as first-line treatment for acute pouchitis (defined as symptom onset <4 weeks). Metronidazole 400 mg three times daily or ciprofloxacin 500 mg twice daily for 14 days is the standard initial approach. Ciprofloxacin is marginally better tolerated and slightly more effective in randomized controlled trials. This empirical strategy targets the dysbiotic microbiota (reduced Faecalibacterium prausnitzii, increased proteolytic anaerobes) and associated inflammation. For recurrent or chronic antibiotic-dependent disease, escalation to maintenance probiotics (VSL#3/Visbiome), rotating antibiotics, or advanced therapies (vedolizumab, ustekinumab, infliximab) is considered. The PDAI score of 9 (≥7 = active) confirms active pouchitis requiring treatment.
Why each distractor is wrong
Conversion to permanent end-ileostomy at first episode: Pouch excision is reserved for chronic antibiotic-refractory pouchitis (CARP) or secondary pouchitis unresponsive to medical therapy, not for the first acute episode. Premature conversion denies the patient the functional benefit of the pouch and is not supported by guidelines.
Long-term high-dose systemic corticosteroids as first line: Systemic corticosteroids are not first-line for acute pouchitis and are reserved for specific scenarios (e.g., CARP with severe inflammation, or when advanced biologics are being initiated). High-dose steroids carry significant morbidity and do not address the underlying dysbiosis. Budesonide MMX (a topical corticosteroid) may be used in selected cases, but not high-dose systemic steroids.
Observation without treatment: Untreated acute pouchitis causes significant morbidity (increased stool frequency, urgency, bleeding, fever) and does not reliably resolve spontaneously. Delaying antibiotic therapy risks progression to chronic or refractory disease and increases the risk of dysplasia over time.
High-YieldNEET PG
Acute pouchitis (first episode, <4 weeks) = empirical 14-day antibiotic course (metronidazole or ciprofloxacin); recurrent/chronic disease requires escalation to maintenance probiotics, rotating antibiotics, or biologic therapy.
AGA Guideline on Management of Pouchitis 2024; Shen Lancet Gastroenterol Hepatol 2019; Madiba & Bartolo BJS 2001
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
